2023-07-15 07:39:25
British consumer healthcare giant Haleon is planning hundreds of job cuts, including some in Switzerland. The company produces certain famous brands of products, in particular at its Vaud site in Nyon-Prangins.
The Voltaren, Panadol, Sensodyne and Nicorette brands, well known to consumers, all belong to Haleon. This young company was born a year ago, the result of a split from the multinational pharmaceutical company GSK.
Due to the aging of the population or the increase in self-medication in particular, the parent company considered that isolating its consumer health branch was wise in view of the favorable socio-economic context.
However, Haleon has suffered cost increases and it wants to avoid this having an impact on the price of its drugs and other products. In fact, she decided to turn to layoffs in order to save money.
The company explains that these changes are being undertaken “to evolve Haleon into a more agile organization.” She reportedly added that “this is part of a broader three-year program that will help increase productivity across the business.”
Probable job cuts in Switzerland
The Swiss site of Haleon, in Nyon-Prangin, is at the heart of regular concerns about job cuts. Already in 2014, the fear of layoffs was felt, and in 2019, a hundred jobs were finally cut.
Of the 24,000 employees worldwide, 1,100 work in Switzerland, particularly in the manufacture of Panadol syrups or Voltaren anti-inflammatory gels.
Contacted by the RTS, the Swiss branch of the company does not give information on future job cuts, but Switzerland will probably be affected. In the 1st quarter, net profits nevertheless reached nearly 440 million francs, an increase of 13% over one year.
Radio subject: Loïc Delacour
Web adaptation: Raphaël Dubois
1689412397
#Pharmaceutical #company #Haleon #plans #cut #hundreds #jobs #rts.ch